Phase 3 trial demonstrates islatravir monthly may be safe for men and transgender women at risk for HIV-1, suggesting potential for prevention.
Islatravir qm was generally well-tolerated; decreases in total lymphocytes were observed with islatravir. Original primary efficacy objectives were not assessed due to early study stoppage.
No takes yet. Share an insight, caveat, or question.
Landovitz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: